Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis

M Müller, S Wandel, R Colebunders, S Attia… - The Lancet infectious …, 2010 - thelancet.com
In patients with HIV-1 infection who are starting combination antiretroviral therapy (ART), the
incidence of immune reconstitution inflammatory syndrome (IRIS) is not well defined. We did …

Progressive multifocal leukoencephalopathy in HIV-1 infection

P Cinque, IJ Koralnik, S Gerevini, JM Miro… - The Lancet infectious …, 2009 - thelancet.com
Progressive multifocal leukoencephalopathy is caused by the JC polyomavirus (JCV) and is
one of the most feared complications of HIV-1 infection. Unlike other opportunistic infections …

[HTML][HTML] Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents

JE Kaplan, C Benson, KK Holmes, JT Brooks, A Pau… - MMWR Recomm …, 2009 - cdc.gov
This report updates and combines earlier versions of guidelines for the prevention and
treatment of opportunistic infections (OIs) in HIV-infected adults (ie, persons aged> 18 years) …

[HTML][HTML] Guidelines for the prevention and treatment of opportunistic infections among HIV-exposed and HIV-infected children: recommendations from CDC, the …

LM Mofenson, MT Brady, SP Danner… - MMWR Recomm …, 2009 - cdc.gov
This report updates and combines into one document earlier versions of guidelines for
preventing and treating opportunistic infections (OIs) among HIV-exposed and HIV-infected …

Incidence, clinical presentation, and outcome of progressive multifocal leukoencephalopathy in HIV-infected patients during the highly active antiretroviral therapy era …

FN Engsig, ABE Hansen, LH Omland… - The Journal of …, 2009 - academic.oup.com
Background. Human immunodeficiency virus (HIV) infection predisposes to progressive
multifocal leukoencephalopathy (PML). Here, we describe the incidence, presentation, and …

Clinical outcomes of natalizumab-associated progressive multifocal leukoencephalopathy

P Vermersch, L Kappos, R Gold, JF Foley, T Olsson… - Neurology, 2011 - AAN Enterprises
Objective: Natalizumab, a therapy for multiple sclerosis (MS), has been associated with
progressive multifocal leukoencephalopathy (PML), a rare opportunistic infection of the CNS …

Progressive multifocal leukoencephalopathy revisited: has the disease outgrown its name?

IJ Koralnik - Annals of Neurology: Official Journal of the …, 2006 - Wiley Online Library
Nothing is more disappointing for patients than when a promising new treatment hits a
roadblock because of unexpected side effects. This is what happened when natalizumab …

Determinants of survival in progressive multifocal leukoencephalopathy

A Marzocchetti, T Tompkins, DB Clifford, RT Gandhi… - Neurology, 2009 - AAN Enterprises
Background: We sought to characterize the role of immunologic, virologic, and radiologic
determinants of survival in patients with progressive multifocal leukoencephalopathy (PML) …

Incidence and outcome of progressive multifocal leukoencephalopathy over 20 years of the Swiss HIV Cohort Study

N Khanna, L Elzi, NJ Mueller, C Garzoni… - Clinical infectious …, 2009 - academic.oup.com
Background. We investigated the incidence and outcome of progressive multifocal
leukoencephalopathy (PML) in human immunodeficiency virus (HIV)–infected individuals …

Fifty years of JC polyomavirus: a brief overview and remaining questions

AL Atkinson, WJ Atwood - Viruses, 2020 - mdpi.com
In the fifty years since the discovery of JC polyomavirus (JCPyV), the body of research
representing our collective knowledge on this virus has grown substantially. As the …